Patents by Inventor Marnix L. Bosch

Marnix L. Bosch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190046568
    Abstract: The present disclosure provides partially mature and activated dendritic cells that produce levels of cytokines/chemokines, for example, one or any combination of and/or all of IL-6, IL-8, IL-12 and/or TNF?, that are correlated with improved clinical outcomes, significantly increased survival times and significantly increased times to tumor or cancer recurrence. The determined threshold amounts of these cytokines can be used for (i) a immunotherapeutic potency test for activated dendritic cells, (ii) selecting responder patients, (iii) rejecting non-responder patients, and (iv) to screen for dendritic cell activation or maturation agents that can also induce the production of the threshold amount of the cytokines/chemokines.
    Type: Application
    Filed: September 14, 2016
    Publication date: February 14, 2019
    Applicant: Northwest Biotherapeutics, Inc.
    Inventor: Marnix L. BOSCH
  • Publication number: 20160024472
    Abstract: The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only GM-CSF without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as IL-4 or IL-13, to prevent differentiation into a non-dendritic cell lineage. The immature DCs generated and maintained in this manner were CD14 and expressed high levels of CD1a. Upon maturation by contact with an agent such as, for example, BCG and IFN?, the cells were determined to express surface molecules typical of mature dendritic cells purified by prior methods and cultured in the presence of GM-CSF and IL-4.
    Type: Application
    Filed: July 30, 2015
    Publication date: January 28, 2016
    Inventors: Benjamin A. Tjoa, Marnix L. Bosch
  • Patent number: 9102917
    Abstract: The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only GM-CSF without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as IL-4 or IL-13, to prevent differentiation into a non-dendritic cell lineage. The immature DCs generated and maintained in this manner were CD14? and expressed high levels of CD1a. Upon maturation by contact with an agent such as, for example, BCG and IFN?, the cells were determined to express surface molecules typical of mature dendritic cells purified by prior methods and cultured in the presence of GM-CSF and IL-4.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: August 11, 2015
    Assignee: Northwest Biotherapeutics, Inc.
    Inventors: Benjamin A. Tjoa, Marnix L. Bosch
  • Publication number: 20130273654
    Abstract: The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only GM-CSF without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as IL-4 or IL-13, to prevent differentiation into a non-dendritic cell lineage. The immature DCs generated and maintained in this manner were CD14? and expressed high levels of CD1a. Upon maturation by contact with an agent such as, for example, BCG and IFN?, the cells were determined to express surface molecules typical of mature dendritic cells purified by prior methods and cultured in the presence of GM-CSF and IL-4.
    Type: Application
    Filed: March 5, 2013
    Publication date: October 17, 2013
    Applicant: Northwest Biotherapeutics, Inc.
    Inventors: Benjamin A. Tjoa, Marnix L. Bosch
  • Patent number: 8518636
    Abstract: The present invention provides tangential flow filtration devices and methods for enriching a heterogenous mixture of blood constituents for leukocytes by removal of non-leukocyte blood constituents. In one particular embodiment the device can provide a composition enriched in monocytes.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: August 27, 2013
    Assignee: Northwest Biotherapeutics, Inc.
    Inventors: Marnix L. Bosch, Paul C. Harris, Steven J. Monahan, Allen Turner, Alton L. Boynton, Patricia A. Lodge
  • Patent number: 8389278
    Abstract: The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only GM-CSF without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as IL-4 or IL-13, to prevent differentiation into a non-dendritic cell lineage. The immature DCs generated and maintained in this manner were CD14? and expressed high levels of CD1a. Upon maturation by contact with an agent such as, for example, BCG and IFN?, the cells were determined to express surface molecules typical of mature dendritic cells purified by prior methods and cultured in the presence of GM-CSF and IL-4.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: March 5, 2013
    Assignee: Northwest Biotherapeutics, Inc.
    Inventors: Benjamin Tjoa, Marnix L. Bosch
  • Publication number: 20120251561
    Abstract: The present invention provides populations of cells comprising partially matured dendritic cells that can be used for administration individuals having a tumor. Partially matured dendritic cells, those contacted with a dendritic cell maturation agent for about 1 to about 10 hours, or more, efficiently take up and process tumor antigens in the area of the tumor site, complete maturation, and can subsequently migrate to the lymph nodes of a treated individual. Once in the lymph node the now fully mature antigen presenting dendritic cells secrete the appropriate cytokines (e.g., TNF? and IL-12) and contact T cells inducing a substantial anti-tumor immune response.
    Type: Application
    Filed: June 4, 2012
    Publication date: October 4, 2012
    Applicant: NORTHWEST BIOTHERAPEUTICS, INC.
    Inventor: Marnix L. Bosch
  • Publication number: 20120244620
    Abstract: The present invention provides methods for inducing the maturation of immature dendritic cells (DC) and for activating those cells without the use of a dendritic cell maturation agent. The activated DC can be used for inducing an antigen specific T cell response. Methods of the invention can also comprise the addition of a directional maturation agent, such as interferon gamma, to induce a Th-1 and/or Th-2 bias in the response obtained. The present invention also provides dendritic cell populations useful for activating and for inducing antigen specific T cells. Similarly, activated antigen specific T cell populations, and methods of making the same are provided.
    Type: Application
    Filed: June 8, 2012
    Publication date: September 27, 2012
    Applicant: NORTHWEST BIOTHERAPEUTICS, INC.
    Inventors: Alton L. Boynton, Marnix L. Bosch
  • Publication number: 20110189150
    Abstract: The present invention provides tangential flow filtration devices and methods for enriching a heterogenous mixture of blood constituents for leukocytes by removal of non-leukocyte blood constituents. In one particular embodiment the device can provide a composition enriched in monocytes.
    Type: Application
    Filed: April 13, 2010
    Publication date: August 4, 2011
    Applicant: Northwest Biotherapeutics, Inc.
    Inventors: Marnix L. Bosch, Paul C. Harris, Steven J. Monahan, Allen Turner, Alton L. Boynton, Patricia A. Lodge
  • Patent number: 7790039
    Abstract: The present invention provides methods for enriching a heterogenous mixture of bone marrow or blood constituents for stem cells by removal of non-stem cell constituents comprising separation of the non-stem cell constituents using a tangential flow filtration device.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: September 7, 2010
    Assignee: Northwest Biotherapeutics, Inc.
    Inventors: Marnix L. Bosch, Patricia A. Lodge, Julie Anna McEarchern, Alton L. Boynton, Paul G. Hugenholtz
  • Patent number: 7695627
    Abstract: The present invention provides tangential flow filtration devices and methods for enriching a heterogeneous mixture of blood constituents for leukocytes by removal of non-leukocyte blood constituents. In one particular embodiment the device can provide a composition enriched in monocytes. One embodiment includes a remover unit (1) having a crossflow chamber (3) separated by a microporous filter (5) from a filtrate chamber (4), the remover unit (1) also having a tangential flow inlet (6), a fluid outlet (7) for a fluid enriched in leukocytes and a filtrate outlet (8).
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: April 13, 2010
    Assignee: Northwest Biotherapeutics, Inc.
    Inventors: Marnix L. Bosch, Paul C. Harris, Steven J. Monahan, Allen Turner, Alton L. Boynton, Patricia A. Lodge
  • Publication number: 20080254537
    Abstract: The present invention provides methods for inducing the maturation of immature dendritic cells (DC) and for activating those cells without the use of a dendritic cell maturation agent. The activated DC can be used for inducing an antigen specific T cell response. Methods of the invention can also comprise the addition of a directional maturation agent, such as interferon gamma, to induce a Th-I and/or Th-2 bias in the response obtained. The present invention also provides dendritic cell populations useful for activating and for inducing antigen specific T cells. Similarly, activated antigen specific T cell populations, and methods of making the same are provided.
    Type: Application
    Filed: December 8, 2006
    Publication date: October 16, 2008
    Applicant: Northwest Biotherapeutics, Inc.
    Inventors: Alton L. Boynton, Marnix L. Bosch
  • Publication number: 20080254064
    Abstract: The present invention provides compositions and methods for inducing maturation of immature dendritic cells (DC) and for priming those cells for inducing a type 1 immune response. The present invention also provides dendritic cell populations useful for activating and for preparing T cells polarized towards production of type 1 cytokines and/or a type 1 response. Similarly, activated, polarized T cell populations, and methods of making the same are provided.
    Type: Application
    Filed: May 29, 2008
    Publication date: October 16, 2008
    Applicant: NORTHWEST BIOTHERAPEUTICS, INC.
    Inventor: Marnix L. Bosch
  • Publication number: 20040203143
    Abstract: The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only GM-CSF without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as IL-4 or IL-13, to prevent differentiation into a non-dendritic cell lineage. The immature DCs generated and maintained in this manner were CD14− and expressed high levels of CD1a. Upon maturation by contact with an agent such as, for example, BCG and IFN&ggr;, the cells were determined to express surface molecules typical of mature dendritic cells purified by prior methods and cultured in the presence of GM-CSF and IL-4.
    Type: Application
    Filed: February 27, 2004
    Publication date: October 14, 2004
    Applicant: Northwest Biotherapeutics, Inc.
    Inventors: Benjamin Tjoa, Marnix L. Bosch
  • Patent number: 6051375
    Abstract: This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are are about 91% identical between RFHV1 and KSHV, and <.about.65% identical to that of other gamma herpes viruses.
    Type: Grant
    Filed: April 28, 1999
    Date of Patent: April 18, 2000
    Inventors: Timothy M. Rose, Marnix L. Bosch, Kurt Strand
  • Patent number: 6022542
    Abstract: This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are are about 91% identical between RFHV1 and KSHV, and <.about.65% identical to that of other gamma herpes viruses.
    Type: Grant
    Filed: September 26, 1996
    Date of Patent: February 8, 2000
    Assignee: University of Washington
    Inventors: Timothy M. Rose, Marnix L. Bosch, Kurt Strand
  • Patent number: 5925733
    Abstract: This invention provides isolated polynucleotides encoding DNA polymerases of three members of a subfamily of gamma herpes viruses. Two were obtained from macaque monkeys affected with retroperitoneal fibromatosis, the other from human AIDS patients affected with Kaposi's sarcoma. A 454-base pair fragment encoding a region near the active site of the DNA polymerase is 69-83% identical amongst the three viruses, but only 54-68% identical with other known gamma herpes sequences and <55% identical with alpha and beta herpes sequences. Also provided are polynucleotides encoding DNA polymerase from related viruses in the RFHV/KSHV subfamily. Polynucleotides prepared according to the sequence data can be used as reagents to detect and characterize related sequences. Such reagents may be used to detect members of the RFHV/KSHV subfamily, including but not limited to RFHV, RFHV2, and KSHV. Corresponding polypeptides and peptide fragments may be obtained by expressing the polynucleotide or by chemical synthesis.
    Type: Grant
    Filed: July 11, 1996
    Date of Patent: July 20, 1999
    Assignee: University of Washington
    Inventors: Timothy M. Rose, Marnix L. Bosch, Kurt Strand, George J. Todaro
  • Patent number: 6015565
    Abstract: This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are are about 91% identical between RFHV1 and KSHV, and <.about.65% identical to that of other gamma herpes viruses.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: January 18, 1999
    Assignee: The University of Washington
    Inventors: Timothy M. Rose, Marnix L. Bosch, Kurt Strand